Sign In
Buy MCRB
$7.17
-0.160 (-2.18%)
At Close: Jun 03, 2026
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2021 Results - Earnings Call Transcript
12:37pm, Tuesday, 03'rd Aug 2021
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2021 Results - Earnings Call Transcript
Recap: Seres Therapeutics Q2 Earnings
07:34am, Tuesday, 03'rd Aug 2021
Shares of Seres Therapeutics (NASDAQ:MCRB) moved higher by 2.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 89.29% year over year to ($0.53),
Why Seres Therapeutics Stock Is Crashing Today
11:51am, Thursday, 22'nd Jul 2021
The company reported disappointing results from a phase 2b clinical study.
MCRB Stock Fell Over 50% Pre-Market: Why It Happened
09:12am, Thursday, 22'nd Jul 2021
The stock price of Seres Therapeutics Inc (NASDAQ: MCRB) fell by over 50% pre-market. This is why it happened.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcas
Seres Therapeutics Stock Plunges As Ulcerative Colitis Candidate Disappoints In Mid-Stage Study
07:22am, Thursday, 22'nd Jul 2021
Seres Therapeutics Inc (NASDAQ: MCRB) has announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The study did no
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock Options
09:46am, Wednesday, 07'th Jul 2021
Investors need to pay close attention to Seres Therapeutics (MCRB) stock based on the movements in the options market lately.
Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021
12:26am, Tuesday, 06'th Jul 2021
Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021
Nestlé Bets $525M On Seres Therapeutics Microbiome Drug For Infectious Diseases
11:01am, Thursday, 01'st Jul 2021
Seres Therapeutics Inc (NASDAQ: MCRB) has inked a $525-million deal with Nestlé Health Science to commercialize SER-109 if it can win FDA approval. SER-109 is an oral, live microbiome therapy under
Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
07:00am, Thursday, 01'st Jul 2021
CAMBRIDGE, Mass. & LAUSANNE, Switzerland--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement wit
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced data from their collaboration with the University of Cologne (Kö
Seres Therapeutics Gets FDA Green Signal to Start SER-155 Human Trials
11:48am, Tuesday, 01'st Jun 2021
The FDA has signed off Seres Therapeutics Inc's (NASDAQ: MCRB) Investigational New Drug (IND) application for SER-155 to initiate Phase 1 trial. SER-155 is a cultivated microbiome therapeutic desi
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal Phase 3 ECO
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will present the latest research from its early stage cli
Seres Therapeutics' SER-287 Is Likely To Succeed In Its Phase 2b Trial
03:25pm, Thursday, 18'th Mar 2021
Fecal microbiota transplantation has succeeded in various randomized ulcerative colitis trials.
